Audrey Saluzzo
About Audrey Saluzzo
Audrey Saluzzo is the Government Affairs Lead at Bristol Myers Squibb, with extensive experience in corporate affairs and account management across various pharmaceutical and healthcare companies.
Current Role at Bristol Myers Squibb
Audrey Saluzzo holds the position of Government Affairs Lead at Bristol Myers Squibb. In this capacity, she focuses on developing the cellular therapy field and influencing significant policy changes. Her responsibilities include briefing the CEO for meetings with high-profile ministers and participating in European working groups and trade associations such as AGIPHARM and LEEM.
Career at Celgene
From 2018 to 2020, Audrey Saluzzo served as Corporate Affairs Lead at Celgene in the Région de Paris, France. During her tenure, she was instrumental in managing corporate affairs and driving strategic policy initiatives.
Professional Experience at UCB
From 2016 to 2018, Audrey Saluzzo worked as Corporate Affairs Lead at UCB. Her work involved developing strategies and managing corporate communications with a focus on influencing health policy within the pharmaceutical industry.
Education and Specialization
Audrey Saluzzo studied at Sciences Po, where she completed a program on lobbying in public administration and parliament in 2021. Additionally, she holds a Master’s degree in management of pharmaceutical industries from IAE France - Business School obtained in 2008. Her academic background has equipped her with expertise in managing and influencing pharmaceutical and medical technology industries.
Industry Expertise and Interests
Audrey Saluzzo has extensive experience across various therapeutic fields including immunology, cardiology, dermatology, gastroenterology, women’s health, hematology, neurosciences, oncology, and more. She has a strong interest in sustainable topics like access to medicines, quality education, gender equality, and reducing inequalities. Her work often focuses on policy changes, including the deletion of clause A in the Social Security Financing Bill and the new decree for hospital certification CAR-T.